Mammalian Genome

, Volume 29, Issue 3–4, pp 260–272 | Cite as

Verification of a genetic locus for methamphetamine intake and the impact of morphine

  • Emily C. Eastwood
  • Amy J. Eshleman
  • Aaron Janowsky
  • Tamara J. Phillips
Article
  • 82 Downloads

Abstract

A quantitative trait locus (QTL) on proximal chromosome (Chr) 10 accounts for > 50% of the genetic variance in methamphetamine (MA) intake in mice selectively bred for high (MAHDR) and low (MALDR) voluntary MA drinking. The µ-opioid receptor (MOP-r) gene, Oprm1, resides at the proximal end of Chr 10, and buprenorphine reduces MA intake in MAHDR mice. However, this drug has only partial agonist effects at MOP-r. We investigated the impact of a full MOP-r agonist, morphine, on MA intake and saccharin intake, measured MOP-r density and affinity in several brain regions of the MA drinking lines and their C57BL/6J (B6) and DBA/2J (D2) progenitor strains, and measured MA intake in two congenic strains of mice to verify the QTL and reduce the QTL interval. Morphine reduced MA intake in the MAHDR line, but also reduced saccharin and total fluid intake. MOP-r density was lower in the medial prefrontal cortex of MAHDR, compared to MALDR, mice, but not in the nucleus accumbens or ventral midbrain; there were no MOP-r affinity differences. No significant differences in MOP-r density or affinity were found between the progenitor strains. Finally, Chr 10 congenic results were consistent with previous data suggesting that Oprm1 is not a quantitative trait gene, but is impacted by the gene network underlying MA intake. Stimulation of opioid pathways by a full agonist can reduce MA intake, but may also non-specifically affect consummatory behavior; thus, a partial agonist may be a better pharmacotherapeutic.

Notes

Acknowledgements

The research presented here was supported by Department of Veterans Affairs Grants I01BX002106 and I01BX002758, National Institutes of Health Grants T32DA07262, P50DA018165, U01DA041579, and R24AA020245, and a National Institutes of Health-Veterans Affairs interagency agreement. The views and opinions expressed are those of the authors and should not be construed to represent the views of the affiliated institutions or the funding agencies. We thank Harue Baba for her help with genotyping and data collection and Robert Johnson for his technical support with the receptor binding assays. We also thank Drs. Glenn Doyle and Thomas Ferraro for provision of the congenic mice from which we established our breeding stock for the current study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted.

References

  1. Abekawa T, Ohmori T, Ito K, Koyama T (2000) D1 dopamine receptor activation reduces extracellular glutamate and GABA concentrations in the medial prefrontal cortex. Brain Res 867:250–254CrossRefPubMedGoogle Scholar
  2. Althobaiti YS, Almalki AH, Das SC, Alshehri FS, Sari Y (2016) Effects of repeated high-dose methamphetamine and ceftriaxone post-treatments on tissue content of dopamine and serotonin as well as glutamate and glutamine. Neurosci Lett 634:25–31CrossRefPubMedGoogle Scholar
  3. Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, Ji X, Takagi K, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iwata N, Inada T, Ozaki N (2006) Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res 30:1644–1649CrossRefPubMedGoogle Scholar
  4. Belknap JK, Richards SP, O’Toole LA, Helms ML, Phillips TJ (1997) Short-term selective breeding as a tool for QTL mapping: ethanol preference drinking in mice. Behav Genet 27:55–66CrossRefPubMedGoogle Scholar
  5. Belknap JK, McWeeney S, Reed C, Burkhart-Kasch S, McKinnon CS, Li N, Baba H, Scibelli AC, Hitzemann R, Phillips TJ (2013) Genetic factors involved in risk for methamphetamine intake and sensitization. Mamm Genome 24:446–458CrossRefPubMedGoogle Scholar
  6. Ben-Shahar OM, Szumlinski KK, Lominac KD, Cohen A, Gordon E, Ploense KL, DeMartini J, Bernstein N, Rudy NM, Nabhan AN, Sacramento A, Pagano K, Carosso GA, Woodward N (2012) Extended access to cocaine self-administration results in reduced glutamate function within the medial prefrontal cortex. Addict Biol 17:746–757CrossRefPubMedPubMedCentralGoogle Scholar
  7. Boas RA, Villiger JW (1985) Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 57:192–196CrossRefPubMedGoogle Scholar
  8. Carr DB, Sesack SR (2000) Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 20:3864–3873PubMedGoogle Scholar
  9. Di Chiara G, Imperato A (1988) Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244:1067–1080PubMedGoogle Scholar
  10. Dlugos AM, Hamidovic A, Hodgkinson C, Shen PH, Goldman D, Palmer AA, de Wit H (2011) OPRM1 gene variants modulate amphetamine-induced euphoria in humans. Genes Brain Behav 10:199–209CrossRefPubMedGoogle Scholar
  11. Doyle GA, Schwebel CL, Ruiz SE, Chou AD, Lai AT, Wang MJ, Smith GG, Buono RJ, Berrettini WH, Ferraro TN (2014) Analysis of candidate genes for morphine preference quantitative trait locus Mop2. Neuroscience 277:403–416CrossRefPubMedPubMedCentralGoogle Scholar
  12. Duttaroy A, Yoburn BC (1995) The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 82:1226–1236CrossRefPubMedGoogle Scholar
  13. Eastwood EC, Phillips TJ (2014a) Opioid sensitivity in mice selectively bred to consume or not consume methamphetamine. Addict Biol 19:370–379CrossRefPubMedGoogle Scholar
  14. Eastwood EC, Phillips TJ (2014b) Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake. Genes Brain Behav 13:226–235CrossRefPubMedGoogle Scholar
  15. Foltin RW, Fischman MW (1996) Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharmacol Exp Ther 278:1153–1164PubMedGoogle Scholar
  16. Gubner NR, Reed C, McKinnon CS, Phillips TJ (2013) Unique genetic factors influence sensitivity to the rewarding and aversive effects of methamphetamine versus cocaine. Behav Brain Res 256:420–427CrossRefPubMedPubMedCentralGoogle Scholar
  17. Harkness JH, Shi X, Janowsky A, Phillips TJ (2015) Trace amine-associated receptor 1 regulation of methamphetamine intake and related traits. Neuropsychopharmacology 40:2175–2184CrossRefPubMedPubMedCentralGoogle Scholar
  18. Iamjan SA, Thanoi S, Watiktinkorn P, Nudmamud-Thanoi S, Reynolds GP (2015) BDNF (Val66Met) genetic polymorphism is associated with vulnerability for methamphetamine dependence. Pharmacogenomics 16:1541–1545CrossRefPubMedGoogle Scholar
  19. Ide S, Kobayashi H, Tanaka K, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Ikeda K, Sora I (2004) Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci 1025:316–324CrossRefPubMedGoogle Scholar
  20. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J (2008a) Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165:1442–1448CrossRefPubMedGoogle Scholar
  21. Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J (2008b) Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 33:1856–1863CrossRefPubMedGoogle Scholar
  22. Jayaram-Lindström N, Guterstam J, Häggkvist J, Ericson M, Malmlöf T, Schilström B, Halldin C, Cervenka S, Saijo T, Nordström AL, Franck J (2017) Naltrexone modulates dopamine release following chronic, but not acute amphetamine administration: a translational study. Transl Psychiatry 7:e1104CrossRefPubMedPubMedCentralGoogle Scholar
  23. Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM (2007) Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. J Pharmacol Exp Ther 323:346–355CrossRefPubMedGoogle Scholar
  24. Lominac KD, McKenna CL, Schwartz LM, Ruiz PN, Wroten MG, Miller BW, Holloway JJ, Travis KO, Rajasekar G, Maliniak D, Thompson AB, Urman LE, Phillips TJ, Szumlinski KK (2014) Mesocorticolimbic monoamine correlates of methamphetamine sensitization and motivation. Front Syst Neurosci 8:70CrossRefPubMedPubMedCentralGoogle Scholar
  25. Lominac KD, Quadir SG, Barrett HM, McKenna CL, Schwartz LM, Ruiz PN, Wroten MG, Campbell RR, Miller BW, Holloway JJ, Travis KO, Rajasekar G, Maliniak D, Thompson AB, Urman LE, Kippin TE, Phillips TJ, Szumlinski KK (2016) Prefrontal glutamate correlates of methamphetamine sensitization and preference. Eur J Neurosci 43:689–702CrossRefPubMedPubMedCentralGoogle Scholar
  26. Lutfy K, Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395–402CrossRefPubMedPubMedCentralGoogle Scholar
  27. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ (2003) Buprenorphine-induced antinociception is mediated by µ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23:10331–10337PubMedGoogle Scholar
  28. Phillips TJ, Shabani S (2015) An animal model of differential genetic risk for methamphetamine intake. Front Neurosci 9:327CrossRefPubMedPubMedCentralGoogle Scholar
  29. Pick CG, Peter Y, Schreiber S, Weizman R (1997) Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Brain Res 744:41–46CrossRefPubMedGoogle Scholar
  30. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T (1994) Pharmacological characterization of the cloned ĸ-, δ-, and µ-opioid receptors. Mol Pharmacol 45:330–334PubMedGoogle Scholar
  31. Sadée W, Rosenbaum J, Herz A (1982) Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 223(1):157–162PubMedGoogle Scholar
  32. Salehi M, Emadossadat A, Kheirabadi GR, Maracy MR, Sharbafchi MR (2015) The effect of buprenorphine on methamphetamine cravings. J Clin Psychopharmacol 35:724–727CrossRefPubMedGoogle Scholar
  33. Schad CA, Justice JB Jr, Holtzman SG (2002) Endogenous opioids in dopaminergic cell body regions modulate amphetamine-induced increases in extracellular dopamine levels in the terminal regions. J Pharmacol Exp Ther 300:932–938CrossRefPubMedGoogle Scholar
  34. Schottenfeld RS, Pakes J, Ziedonis D, Kosten TR (1993) Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry 34:66–74CrossRefPubMedGoogle Scholar
  35. Shabani S, McKinnon CS, Reed C, Cunningham CL, Phillips TJ (2011) Sensitivity to rewarding or aversive effects of methamphetamine determines methamphetamine intake. Genes Brain Behav 10:625–636CrossRefPubMedPubMedCentralGoogle Scholar
  36. Shabani S, Dobbs LK, Ford MM, Mark GP, Finn DA, Phillips TJ (2012a) A genetic animal model of differential sensitivity to methamphetamine reinforcement. Neuropharmacology 62:2169–2177CrossRefPubMedGoogle Scholar
  37. Shabani S, McKinnon CS, Cunningham CL, Phillips TJ (2012b) Profound reduction in sensitivity to the aversive effects of methamphetamine in mice bred for high methamphetamine intake. Neuropharmacology 62:1134–1141CrossRefPubMedGoogle Scholar
  38. Shabani S, Houlton SK, Hellmuth L, Mojica E, Mootz JR, Zhu Z, Reed C, Phillips TJ (2016) A mouse model for binge-level methamphetamine use. Front Neurosci 10:493CrossRefPubMedPubMedCentralGoogle Scholar
  39. Shi X, Walter NA, Harkness JH, Neve KA, Williams RW, Lu L, Belknap JK, Eshleman AJ, Phillips TJ, Janowsky A (2016) Genetic polymorphisms affect mouse and human trace amine-associated receptor 1 function. PLoS ONE 11:e0152581CrossRefPubMedPubMedCentralGoogle Scholar
  40. Shifman S, Bell JT, Copley RR, Taylor MS, Williams RW, Mott R, Flint J (2006) A high-resolution single nucleotide polymorphism genetic map of the mouse genome. PLoS Biol 4:e395CrossRefPubMedPubMedCentralGoogle Scholar
  41. Szumlinski KK, Lominac KD, Campbell RR, Cohen M, Fultz EK, Brown CN, Miller BW, Quadir SG, Martin D, Thompson AB, von Jonquieres G, Klugmann M, Phillips TJ, Kippin TE (2017) Methamphetamine addiction vulnerability: the glutamate, the bad, and the ugly. Biol Psychiatry 81:959–970CrossRefPubMedGoogle Scholar
  42. Taber MT, Fibiger HC (1995) Electrical stimulation of the prefrontal cortex increases dopamine release in the nucleus accumbens of the rat: modulation by metabotropic glutamate receptors. J Neurosci 15:3896–3904CrossRefPubMedGoogle Scholar
  43. Wang PC, Ho IK, Lee CW (2015) Buprenorphine-elicited alteration of adenylate cyclase activity in human embryonic kidney 293 cells coexpressing ĸ-, µ-opioid and nociceptin receptors. J Cell Mol Med 19:2587–2596CrossRefPubMedPubMedCentralGoogle Scholar
  44. Wheeler JM, Reed C, Burkhart-Kasch S, Li N, Cunningham CL, Janowsky A, Franken FH, Wiren KM, Hashimoto JG, Scibelli AC, Phillips TJ (2009) Genetically correlated effects of selective breeding for high and low methamphetamine consumption. Genes Brain Behav 8:758–771CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature (outside the USA) 2017

Authors and Affiliations

  1. 1.Department of Behavioral NeuroscienceOregon Health & Science UniversityPortlandUSA
  2. 2.Methamphetamine Abuse Research CenterOregon Health & Science UniversityPortlandUSA
  3. 3.Department of PsychiatryOregon Health & Science UniversityPortlandUSA
  4. 4.Veterans Affairs Portland Health Care SystemPortlandUSA
  5. 5.VA Portland Health Care SystemPortlandUSA
  6. 6.Department of Human BiologyFred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations